^
Association details:
Biomarker:No biomarker
Cancer:Anal Carcinoma
Drug:Opdivo (nivolumab) (PD1 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
…the panel added nivolumab and pembrolizumab as preferred options for patients with metastatic anal cancer who have progressed for the on first-line chemotherapy…